The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Personalized neoantigen DNA vaccines expand tumor-specific T cells in the periphery which infiltrate the tumor in hepatocellular carcinoma.
 
Renzo Perales
Employment - Geneos
 
Mark Yarchoan
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Genentech/Roche; Hepion Pharmaceuticals; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Merck
 
Neil Cooch
Employment - Geneos
 
Niranjan Sardesai
Employment - BMS (I); Geneos
Leadership - Geneos
Stock and Other Ownership Interests - BMS (I); Geneos; Inovio Pharmaceuticals; Merck (I)
Patents, Royalties, Other Intellectual Property - I am an inventor on several patents assigned to my current and former employers Geneos Therapeutics and Inovio Pharmaceuticals respectively. As these are assigned to the company I receive no royalties or will receive no royalties on these patents.
 
Alfredo Perales-Puchalt
Employment - Geneos; Inovio Pharmaceuticals
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline; Globus; IgM Biosciences; Merck; Pfizer; Vanda Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Methods and compositions for treating cancer - WO2016054153A1 Optimized Synthetic Consensus Immunogenic Compositions Targeting the Follicle Stimulating Hormone Receptor (FSHR) - WO2018044929A1 (Inst)